Synthon Approach in Crystal Engineering to Modulate Physicochemical Properties in Organic Salts of Chlorpropamide
Authors:
- 30 April 2024
- journal article
- research article
- Published by American Chemical Society (ACS) in Molecular Pharmaceutics
- Vol. 21 (6) , 2894-2907
Abstract
The formulation of drug with improved bioavailability is always challenging and indispensable in the field of pharmaceutics. The control of intermolecular interactions via crystal engineering approach and solid-state molecular recognition results in the formation of active drug molecules with modulated pharmacological benefits. Therefore, with the aim to improve the solubility and dissolution rate of the drug chlorpropamide (CPA), the mechanochemical liquid-assisted grinding (LAG) of the drug with several pharmaceutically accepted excipients was performed. This contributed to the discovery of six novel solid phases, namely salts, salt cocrystals and salt cocrystal hydrate─the salt of CPA with 3, 4-diaminopyridine (DAP); salt and salt cocrystal (SC) polymorph (Z″=3) with 1, 4-diazabicyclo [2.2.2] octane (DABCO); a salt, SC polymorph (Z″=9), and a SC hydrate (Z″=9) with piperazine (PIP). The formation of these salts and salt cocrystals are mainly guided by the strong hydrogen bonds with tunable strength having high electrostatic contribution. This attractive interaction brings the donor and the acceptor atoms close to each other for a facile proton transfer. Furthermore, the conformational constraints on the drug molecules, provided by the excipients via strong and directional hydrogen bonds, are quite impressive as this leads to the identification and characterization of "new conformational isomers" for the CPA molecules. The new crystalline phases exhibit enhanced intrinsic dissolution rate in comparison to that of the pure drug, the magnitude being 7, 131, and 120 folds for CPADAP, CPADABCO_II, and CPAPIP_III, respectively. Furthermore, it is interesting to note that the order of solubility is enhanced by 2.7-, 3-, and 7-fold, respectively, for the abovementioned salts. This also mirrors the trends in the magnitude of the binding energy, the higher magnitude being reflected in the lower solubility. Additionally, the in vivo experiments performed in SD rats results in the enhancement of the magnitude of the pharmacokinetic properties, when compared to the pristine drug. The concentration of the drug in CPADABCO_II and CPAPIP_III formulations exhibits 6- and 4-fold increments, respectively. Indeed, these results corroborate to the trends observed in the structural characterization, intermolecular energy calculations, solubility, and in vitro dissolution assessments.Keywords
Funding Information
- University Grants Commission
- Anusandhan National Research Foundation (EMR/2016/006835, EMR/2016/06835)
This publication has 45 references indexed in Scilit:
- Entacapone Polymorphs: Crystal Structures, Dissolution, Permeability, and StabilityCrystal Growth & Design, 2021
- Multicomponent Crystals of Chlorpropamide: Multiple Conformers, Multiple Z′, and Proton Transfer at PlayCrystal Growth & Design, 2021
- Recent developments in pharmaceutical salts: FDA approvals from 2015 to 2019Drug Discovery Today, 2021
- Particle Size Reduction Techniques of Pharmaceutical Compounds for the Enhancement of Their Dissolution Rate and BioavailabilityJournal of Pharmaceutical Innovation, 2021
- Improving solubility and intrinsic dissolution rate of ofloxacin API through salt formation via mechanochemical synthesis with diphenic acidJournal of Molecular Structure, 2020
- Pharmaceutical aspects of salt and cocrystal forms of APIs and characterization challengesAdvanced Drug Delivery Reviews, 2017
- Spring and parachute: How cocrystals enhance solubilityProgress in Crystal Growth and Characterization of Materials, 2016
- Pharmacokinetics in Drug Discovery: An Exposure-Centred Approach to Optimising and Predicting Drug Efficacy and Safety2015
- Particle Size Analysis in Pharmaceutics: Principles, Methods and ApplicationsPharmaceutical Research, 2006
- Correction Factor for Dissolution Profile CalculationsJournal of Pharmaceutical Sciences, 1993